Stem cells, exosomes, gene therapy, peptides, hyperbaric oxygen, and epigenetic reprogramming
390 articles
Three days of GDF11 infusion post-injury preserved pericytes, protected the blood-spinal cord barrier, and improved functional recovery in mice.
A new laser-based technique repairs vacuum-dehydrated proteins on cryoEM grids, achieving near-native resolution comparable to conventional plunge freezing.
PARP inhibitors have transformed cancer treatment, but resistance and toxicity are emerging as serious limits to their long-term effectiveness.
A miniaturized PEMF device failed to raise SpO2 in healthy rats, suggesting COVID-19 benefits may be disease-specific.
A CRISPR-based adenine base editor restores CFTR function in airway cells and intestinal organoids from CF patients with a previously undruggable mutation.
Regeneron's Otarmeni marks a historic milestone as the first FDA-approved gene therapy targeting a rare genetic form of hearing loss.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity — potentially replacing daily weight loss drugs.
A novel PEMF device non-destructively monitors steel structural joints, detecting early degradation with 30% greater sensitivity than conventional techniques.
A preclinical rat study finds pulsed electromagnetic field therapy applied remotely cuts fracture healing time from 30 to 23 days and eliminates post-surgical abscesses.
A cross-species bacterial genome editing platform achieves >90% efficiency in two species, opening doors for microbiome and probiotic engineering.
Une plongée mécaniste rigoureuse dans la logique moléculaire de la reprogrammation partielle — de la dynamique de la chromatine et du renversement des horloges épigénétiques aux stratégies de délivrance in vivo, aux risques oncogènes et à la voie vers la translation clinique.
The AACR 2026 conference spotlights emerging cancer therapeutics — from targeted therapies to immunotherapy advances — with direct implications for longevity.
